Revolution Medicines, Inc. (RVMD) analyst actions
Rating and price-target actions on RVMD in the public-source dataset. Wires and filings carry few rating actions, so this list is sparse by nature — the hub's by-event-type table holds the measured analyst base rates. Back to the RVMD overview →
1 measured RVMD analyst action event.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| Revolution Medicines Shares New Clinical Results Supporting Initiation of RASolute 303, a Global Phase 3 Registrational Trial of Daraxonrasib in First Line Metastatic Pancreatic Ductal Adenocarcinoma | Press release | +1.98% | +7.79% |
Keep exploring
More RVMD: earnings → · SEC filings → · RVMD overview →